Inflammation is a biological response intended to protect the organism from infections, injuries and other harmful stimuli. The inflammatory response can produce an excessive accumulation of leukocyte, which can lead to asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis, septic shock and various other diseases. Tissue fibrosis and abnormal organ function can also occur during the inflammation response if there is an over-production and deposition of collagens. Fibrosis remains the leading cause of death in the United Sates; approximately 45% of deaths are related to fibrosis, doubling the number of cancer related deaths. Liver and kidney fibrosis are two common fibrosis diseases that are caused by excessive inflammation in the respective organ Heart muscle fibrosis also known as cardiac fibrosis is a result of coronary heart disease and an irregular thickening of heart valves. In China, liver cirrhosis, an advanced form of liver fibrosis, is one of the most common threats to health; usually caused by hepatitis and alcohol abuse. A majority of SARS related deaths are a result of pulmonary fibrosis in late-stage patients.

The small-molecule compound F351, developed by Shanghai Genomics as a non-steroid anti-inflammation drug, can block the key step in the process leading to fibrosis. By significantly reducing the synthesis and the deposition of collagens inside the liver, kidney, lung, and skin tissues, the drug can combat pulmonary fibrosis, liver cirrhosis and skin scar formation. F351’s, non-toxicity, as shown in animal tests and in-vitro experiments, and low manufacturing costs, makes this compound an excellent oral drug candidate.

© 2007~2018 All rights reserved. Shanghai ICP 08017875